December 17, 2020
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549-3561
| Attn: | David Gessert |
| Re: | Novus Therapeutics, Inc. Registration Statement on Form S-3, filed December 11, 2020, file No. 333-251305 |
Dear Mr. Gessert,
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-251305) of Novus Therapeutics, Inc. so that it may become effective at 4:00 p.m., Eastern Time, on December 22, 2020, or as soon as possible thereafter.
If you have any questions, please contact Ryan A. Murr (415-393-8373) of Gibson, Dunn & Crutcher LLP.
| Sincerely, | ||
| NOVUS THERAPEUTICS, INC. | ||
| By: | /s/ David-Alexandre C. Gros | |
| David-Alexandre C. Gros | ||
| Chief Executive Officer | ||
| cc: | Ryan A. Murr, Gibson, Dunn & Crutcher LLP |